Development of Intranasal Deformable Ethosomes of Rasagiline Mesylate for The Effective Management of Parkinsonism (Research Article)

Author(s): Neelima Mishra*, Dilip Kumar Tiwari, Kaushelendra Mishra, Akshat Gupta, Saurav Suman and Suchismita Mishra

Abstract: Intranasal deformable ethosomes for Rasagiline mesylate was developed for effective treatment of Parkinson’s disease. Ethosomes were prepared by ethanol injection method. D-optimal design was applied for formulation optimization. Ethanol, propylene glycol and phospholipids were selected as independent variables while encapsulation efficiency (EE) of the ethosomes as dependent variable. The optimum formulation of RM ethosomes, in which ethanol (34.3%), propylene glycol (13.2%) and phospholipids (4.1%) has higher EE of 38% with spherical bilayered structure revealed from TEM analysis, average particle size range of 256 nm and zeta potential values obtained as -24.4mV. Further in- vitro drug diffusion studies were carried out through nasal mucosa of sheep and the cumulative amount diffused was reported as 766μg/cm2. These results confirmed that ethosomes has potential for nose to brain delivery system of Rasagiline mesylate for treatment of Parkinson’s disease.

PAGES: 25-33  |  29 VIEWS  57 DOWNLOADS